相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
Mei-Mei Zheng et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial
Zhi-qin Lu et al.
THORACIC CANCER (2021)
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615)
Chengjuan Fan et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Original Research Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments
Mei-Mei Zheng et al.
EUROPEAN JOURNAL OF CANCER (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C. H. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
S. Park et al.
ANNALS OF ONCOLOGY (2020)
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Jiyun Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
Lizza E. L. Hendriks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng et al.
LANCET ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer
Yun Fan et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101)
Keiichi Ota et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells
Ben-Yuan Jiang et al.
CLINICAL CANCER RESEARCH (2017)
Therapy of leptomeningeal metastasis in solid tumors
F. Mack et al.
CANCER TREATMENT REVIEWS (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Zhenfan Yang et al.
Science Translational Medicine (2016)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Bin-Chi Liao et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
Justine L. Kuiper et al.
LUNG CANCER (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
David M. Jackman et al.
ONCOTARGET (2015)
Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era
Jonathan W. Riess et al.
CLINICAL LUNG CANCER (2014)
Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors
Su Jin Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
Jin Hyun Park et al.
LUNG CANCER (2012)
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy
Takeshi Masuda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes et al.
NEURO-ONCOLOGY (2011)
分享论文
